Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Gabexate”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources
PubMed1984

Gabexate mesilate (Foy) as an anticoagulant in extracorporeal circulation in dogs and sheep.

Gabexate mesilate (GM), a synthetic serine protease inhibitor with a short half-life time of approx. 80 sec, was applied as the exclusive anticoagulant in small scale extracorporeal circulation in narcotized dogs and sheep. The animals underwent a veno-venous bypass. As the blood was drawn out of the femoral vein, GM was infused immediately into the extracorporeal system. GM was greatly reduced because of its short half-life time before the blood reentered the animal via a brachial vein. In order to control the coagulatory state of the blood, the Activated Clotting Time (ACT), Partial Thromboplastine Time (PTT) and Recalcification Time (RT) were measured in regular intervals. In addition, a screen pressure test device was used to monitor on line during ECC the tendency of blood clotting. It was shown that the blood of the extracorporeal system was sufficiently anticoagulated by an infusion of 0.03 mg/ml/min GM. During two hours ECC, simultaneously measured ACT-values of the animals only differed up to 10 percent from the native values. Pilot studies have shown that the results of these model investigations could be successfully transferred to extracorporeal circulation with membrane oxygenators and pumps as they are clinically used.

Animals↗
PubMedDate not supplied

Gabexate mesilate in the treatment of acute pancreatitis.

Despite controversial experimental and clinical findings, the use of Aprotinin (A) in the treatment of acute pancreatitis (AP) is still widespread in our country. Compared to A, Gabexate Mesilate (FOY) should have the following advantages: lack of antigenicity, low molecular weight with better cellular penetrance, wide inhibitory spectrum (against phospholipase A2 too) and good tolerability. In order to verify the efficacy of FOY versus, we decided to carry out a prospective multicenter (34 centers) randomized double blind trial in moderate-severe AP with FOY 3g/day versus A 1,500,000 U.I.K./day infused for 7 days with central venous line. Based on standard clinical, biochemical and radiological data, 199 patients suffering from AP were enrolled to the study from January 1989 to December 1990. The main admission criteria were: onset of the disease from no more than 72 hours, at least 2 Ranson positive criteria and C.T. evidence of acute pancreatic damage. Seventeen no protocol patients were excluded. The Etiology in the 182 analyzed patients (106 male, 76 female; mean age 57.6 years, range 21-91) were: biliary 102 (56%), alcohol 47 (25.8%), post-operative 13 (7.1%), unknown causes 13 (7.1%) and others 7 (3.8%). Median Ranson's Score was 3. CT examination showed 66 AP with edema, while 116 cases (63.7%) were recognized as severe forms with pancreatic necrotic involvement of 30% of the gland in 71 (61.2%), 50% in 31 (26.7%), and more than 50% in 14 (12.1%). Out of 182 patients, 91 were treated with A and 91 with FOY. The two groups were comparable regarding the main prognostic factors.(ABSTRACT TRUNCATED AT 250 WORDS)

Acute Disease↗
PubMed1994

The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis.

This study was undertaken to determine whether synthetic proteinase inhibitors--nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) have any influence on multiorgan oxidant-antioxidant balance in acute haemorrhagic pancreatitis induced in Wistar rats using a retrograde intraductal injection of 5% Na-taurocholate. Rats were treated with FUT-175 25 x 10(-3) g.kg-1.h-1) or FOY (2.5 x 10(-3) g.kg-1.h-1) and sacrificed at 3 h. Malondialdehyde and sulfhydryl groups concentration, as an index of oxidative stress, we measured in pancreatic, lung and liver tissue. In rats with acute pancreatitis treated with these proteinase inhibitors, oxidative stress expressed by malondialdehyde elevation and sulfhydryl groups depletion, was markedly diminished. It was observed in the pancreas and lung, and to a lesser extent in the liver. These effects of FUT-175 or FOY treatment, at least in part, may account for recently postulated favorable systemic effects of such a medication.

Acute Disease↗
PubMedDate not supplied

Treatment of disseminated intravascular coagulation with gabexate mesilate.

Gabexate mesilate (FOY) was used to treat 215 patients with disseminated intravascular coagulation (DIC) and 146 patients with a predisposition to DIC (pre-DIC). Sixty percent of DIC patients and 48% of pre-DIC patients exhibited pretreatment organ failure, which resolved after FOY treatment in 16% of DIC patients and 17% of pre-DIC patients. Seventy percent of DIC patients and 49% of pre-DIC patients had a pretreatment bleeding tendency that was ameliorated by FOY treatment in 32% of DIC patients and 30% of pre-DIC patients. Comparison of pretreatment and posttreatment hemostatic studies of the DIC patients revealed that platelet count and levels of fibrinogen degradation products (FDP), thrombin-antithrombin-III complex, and FDP-D-dimer decreased significantly; fibrinogen level increased markedly; and prothrombin time was prolonged. DIC scores were significantly lowered in both leukemic and nonleukemic patients from the third day of treatment with FOY. Among leukemic DIC patients, 59% showed complete remission (CR), 21% partial remission (PR), and 7% exacerbation of their condition; 46% of the nonleukemic DIC patients demonstrated CR, 17% PR, and 17% exacerbation. Of the leukemic pre-DIC patients, 59% showed improvement and 7% exacerbation, whereas 55% of the nonleukemic pre-DIC patients showed improvement and 27% exacerbation.

Disseminated Intravascular Coagulation↗
PubMed1979

Inhibitory effects of gabexate mesilate (FOY) on experimental DIC.

The inhibitory effects of a newly synthesized protease inhibitor, Gabexate mesilate (FOY), on experimental disseminated intravascular coagulation were studied as compared with those of aprotinin or heparin. Thrombin, tissue thromboplastin, and endotoxin were used as DIC trigger substances. As parameters on DIC, platelet counts, white blood cell counts, neutrophilic leukocyte counts, fibrinogen, fibrin degradation products, platelet retention, platelet aggregation, prothrombin time, partial thromboplastin time were served. The drug efficacy in each parameter were expressed by the score system and analyzed statistically. The results were summarized as follows; (1) In thrombin-induced DIC, FOY was apparently superior to the other drugs (p less than 0.05). (2) In thromboplastin-induced DIC, heparin was slightly more effective than FOY or aprotinin. (3) In endotoxin infusion, there were no significant differences among them. In conclusion, the results of the present study suggest that FOY was more effective than heparin or aprotinin on experimental DIC.

Animals↗
PubMed1986

Cellular (thrombocytes, granulocytes) effects of proteinase inhibitors--gabexylate, gabexate mesilate (FOY) and aprotinin.

Because of the involvement of proteinases in the activation mechanism of thrombocytes and granulocytes, the effect of proteinase inhibitors was tested. To document cell activation we used thrombocyte and granulocyte aggregation. Chemiluminescence and superoxide production were used as parameters for the release of activated oxygen compounds, and lysozyme as a marker of lysosomal enzyme release. FOY and aprotinin inhibited all but not arachidonic acid thrombocyte aggregation. Only aprotinin diminished granulocyte responses to various stimuli, while FOY was without effect at concentration less than 100 microM.

Aprotinin↗
PubMed1991

[Effects of gabexate mesilate (FOY) on the gallbladder, sphincter of Oddi and duodenum of the normal and gastrectomized dogs].

FOY induced a dose-dependent inhibitory response on the gallbladder, sphincter of Oddi and duodenum of normal and gastrectomized dogs, although it induced an excitatory response in some dogs. The inhibitory response was not reduced or terminated by pretreatment with atropine, guanethidine, hexamethonium or/and proglumide. The FOY-induced inhibitory response reversed to the excitatory response in the sphincter of Oddi and duodenum by pretreatment with tetrodotoxin, but not in the gallbladder. These results suggested that the FOY-induced inhibitory response of the sphincter of Oddi and duodenum was caused by stimulation of nonadrenergic noncholinergic inhibitory neurons, not by FOY-induced cholecystokinin secretion. The excitatory response was induced by direct stimulation of their smooth muscles. The inhibitory response of the gallbladder to FOY was induced by direct stimulation of the smooth muscles.

Animals↗